MacroGenics financials
$3.86+2.39%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $149.5M | $150.0M | $58.7M | $151.9M | $77.4M | $104.9M | $64.2M | $60.1M | $157.7M | $91.9M |
| Gross profit | $113.5M | $137.7M | $50.5M | $144.6M | $74.8M | $104.9M | $64.2M | $60.1M | $157.7M | $91.9M |
| Gross margin | 75.9% | 91.8% | 86.0% | 95.1% | 96.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$72.8M | -$110.6M | -$168.2M | -$121.4M | -$202.8M | -$131.1M | -$177.2M | -$171.2M | -$22.1M | -$60.0M |
| Net income | -$74.6M | -$67.0M | -$9.1M | -$119.8M | -$202.1M | -$129.7M | -$151.8M | -$171.5M | -$19.6M | -$58.5M |
| Net margin | −49.9% | −44.7% | −15.4% | −78.8% | −261.0% | −123.7% | −236.5% | −285.2% | −12.4% | −63.7% |
| Diluted EPS | $-1.18 | $-1.07 | $-0.15 | $-1.95 | $-3.37 | $-2.47 | $-3.16 | $-4.19 | $-0.54 | $-1.69 |
| EBITDA | -$65.7M | -$103.0M | -$158.6M | -$109.6M | -$191.5M | -$119.1M | -$164.9M | -$162.0M | -$14.9M | -$52.4M |
| Operating cash flow | -$81.0M | -$68.4M | -$78.2M | -$87.0M | -$143.8M | -$111.9M | -$134.3M | -$153.2M | $14.4M | -$43.7M |
| Free cash flow | -$83.0M | -$72.1M | -$80.0M | -$90.6M | -$150.0M | -$117.8M | -$138.6M | -$178.2M | -$15.0M | -$55.1M |
| Diluted shares | 63.2M | 62.6M | 61.9M | 61.4M | 59.9M | 52.4M | 48.1M | 40.9M | 36.1M | 34.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $57.2M | $182.8M | $101.0M | $108.9M | $123.5M | $181.1M |
| Short-term investments | $132.7M | $18.8M | $128.8M | $45.5M | $120.1M | $91.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $256.8M | $261.7M | $298.4M | $280.5M | $335.2M | $378.7M |
| Total liabilities | $201.3M | $145.6M | $145.8M | $138.5M | $95.6M | $82.9M |
| Shareholders' equity | $55.6M | $116.1M | $152.6M | $142.0M | $239.6M | $295.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology